Annotation Detail
Information
- Associated Genes
- NTRK3
- Associated Variants
- NTRK3 NTRK3 FUSIONS NTRK3 NTRK3 FUSIONS
- Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- This was a Phase 1/2 study of 55 patients from 4 months to 76 years old with TRK-fusion positive tumors given NTRK inhibitor Larotrectinib. Patients had 17 unique NTRK fusion types. Patient overall response rate was 75% according to independent review and 80% according to investigator assessment. Authors state that Larotrectinib had durable anti tumor activity regardless of age or tumor type. 26/27 patients with NTRK3-fusion showed maximum percent change in tumor size between -30% and -100%.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6568
- Gene URL
- https://civic.genome.wustl.edu/links/genes/3985
- Variant URL
- https://civic.genome.wustl.edu/links/variants/1277
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Larotrectinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 29466156
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Larotrectinib | Sensitivity | true |